American Association for Cancer Research

Cancer Epigenetics

May 28 - 31, 2008
Boston Park Plaza Hotel
Boston, Massachusetts

VIEW PROGRAM

DOWNLOAD BROCHURE


CHAIRPERSONS:
Jean-Pierre J. Issa
UT M. D. Anderson Cancer Center, Houston, TX

Peter W. Laird
USC/Norris Comprehensive Cancer Center, Los Angeles, CA

Cancer Epigenetics


The study of epigenetic mechanisms in cancer, such as DNA methylation, histone modifications, nucleosome positioning and micro-RNA expression, has revealed a plethora of events that contribute to the neoplastic phenotype through stable changes in the expression of genes critical to transformation pathways. In the 10 years since the first AACR Special Conference on cancer epigenetics (in 1997), the field has grown exponentially in knowledge, publications, and number of investigators. Most encouragingly, research in epigenetics has led to improved survival of patients with certain forms of lymphoma and leukemias through the use of drugs that alter DNA methylation and histone acetylation. In addition, there are numerous other clinical applications of the field being explored in areas such as cancer screening and early detection, prevention, classification for epidemiology and prognostic purposes, and predicting outcomes after standard therapy.

This AACR Special Conference on cancer epigenetics will assemble prominent investigators in the field to discuss recent advances in this rapidly moving area. Sessions will review mechanisms and recent advances in whole genome epigenetic analysis of cancer. Several sessions will examine specific clinical applications such as diagnostics and therapeutics, and workshops will discuss practical research and translational issues such as methods of whole genome epigenetic analysis and definition of hypermethylator phenotypes. Ample time has been reserved for discussion, oral presentation of selected submitted abstracts, and late breaking research. This conference will provide a unique forum to review the remarkable progress in this area over the past few years, and provide a glimpse of where the field is moving, including a strong emphasis of translational epigenetics research.

Know a colleague who might be interested in this conference?